newsfilter
← Latest News
ACCESS Newswire·

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

SNOA
  • Total revenue increased 60% year over year to $6.4 million for the quarter ended June 30, 2026.
  • Net loss per share decreased 88% compared to the prior-year quarter, with the net loss narrowing to $0.3 million from $1.2 million.
  • Gross margin expanded to 40% as operating expenses remained stable at $2.6 million despite revenue growth.
  • The company achieved positive adjusted EBITDA of $0.1 million for the first time in its history.
  • U.S. revenue grew 141% to reflect increased sales of over-the-counter products & new distributor activity.
  • European revenue increased 34% driven by higher demand & favorable exchange rates.
  • Sonoma received new FDA 510(k) clearance in June 2026 for Microdacyn® Wound Irrigation Solution with expanded claims.
  • New distributors were added in Taiwan, Vietnam, & the United States since the start of fiscal year 2027.
  • Cash & cash equivalents increased to $5.3 million as of June 30, 2026.
  • Common stock issued & outstanding rose to 4,785,801 shares from 1,799,057 shares in the prior period.